Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News
May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

May 6th 2025

18MWT Contributes Valuable Feedback in Setting of PAH

April 28th 2025

PH, PAH Prevalence Higher in Medicaid, With Racial, Ethnic Disparities

April 21st 2025

Wearable Tech Has Potential to Indicate PAH-Related Decline

April 8th 2025

Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score

Video Interviews
View All
March 31st 2025

ZENITH Trial Findings Could Reshape PAH Treatment, Extending Sotatercept’s Reach

June 12th 2024

Addressing Unmet Needs in the PAH Landscape

June 12th 2024

Optimizing PAH Care Delivery for Better Outcomes

June 5th 2024

Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

May 29th 2024

Overcoming Barriers to Better Patient Outcomes in PAH

May 22nd 2024

FDA Approves Sotatercept for Pulmonary Arterial Hypertension

May 15th 2024

Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

May 6th 2024

A New Era in PAH Treatment?

May 6th 2024

Breaking Down the PAH Cost Burden

May 3rd 2024

Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

More News

PAH | Image Credit: © Richelle-stock.adobe.com
April 4th 2025

Burden of PAH Weighs Heavy Worldwide

Maggie L. Shaw
Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national burdens in pulmonary arterial hypertension (PAH).
Glass pharmaceutical vials | Image credit: ronnarong – stock.adobe.com
March 31st 2025

Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH

Hayden E. Klein
Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.
Pulmonary hypertension | Image Credit: © Uladzislau-stock.adobe.com
March 26th 2025

PAH Therapies Improve Outcomes in PH-ILD

Maggie L. Shaw
Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Hypertension | Image Credit: © jeffy1139-stock.adobe.com
March 24th 2025

Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials

Connor Iapoce
New topline data from the Launch-HTN (NCT06153693) and Advance-HTN (NCT06153693) clinical trials show these investigations met their primary end points os statistically significant reductions in systolic blood pressure.
Patients with PAH had distinct PA flow characteristics compared with those with PH-HFpEF. | Image credit: Thirawat - stock.adobe.com
March 21st 2025

Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics

Jared Kaltwasser
Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Measuring BP in pregnancy | Image Credit: ©Mediteraneo-stock.adobe.com
March 18th 2025

Managing Pulmonary Hypertension in Pregnancy

Maggie L. Shaw
Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are pregnant are considered a high-risk population, and they face higher rates of maternal and fetal complications.
Congenital heart disease | Image Credit: © ibreakstock-stock.adobe.com
March 14th 2025

PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease

Maggie L. Shaw
Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Hyperuricemia may be an important risk factor for pulmonary arterial hypertension. | Image credit: jarun011 - stock.adobe.com
January 3rd 2025

High Uric Acid Appears to Have Causal Role in PAH

Jared Kaltwasser
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension (PAH).
A new report suggests that patients with PAH consistently report higher symptom burden than their physicians do for their condition | image credit: bongkarn - stock.adobe.com
December 30th 2024

People With PAH Report Higher Symptom Burden Than Their Physicians

Jared Kaltwasser
Patients and physicians agree about which symptoms have the biggest impact on patients’ quality of life.
Top 5 PAH Articles of 2024
December 29th 2024

Top 5 Most-Read PAH Articles of 2024

Julia Bonavitacola
The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes on hypertension, and how diagnosis time affects outcomes.
Heart | Image credit: appledesign - stock.adobe.com
December 19th 2024

Researchers Characterize Limitations With Methods of Determining IVS Flattening in PH

AJMC Contributor
Based on their findings, the researchers suggest the integration of automated measures to identify interventricular septal (IVS) flattening in these patients.
PAH | Image Credit: © Kiattisak-stock.adobe.com
December 12th 2024

New Study Evaluates Quality-of-Life Instruments for Patients With PAH

Kimberly Rath, PharmD
A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.
Lung analysis concept | image credit: Shahidah - stock.adobe.com
December 8th 2024

Nanoparticle Delivery Holds Promise for Treatment of PAH

Karen Jacobson-Sive
Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.
Chest X-ray for lung health assessment | image credit: Radiographys - stock.adobe.com
December 5th 2024

Slow, Steady Advances: Noninvasive Diagnosis of PH in ILD Populations

Gayle Turim Dickstein
Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help improve the landscape.
patient taking pills | Image Credit: © fizkes - stock.adobe.com
November 24th 2024

Communication Can Boost Medication Persistence in PAH

Jared Kaltwasser
Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey.
Doctor with hands holding an image of lungs | Image credit: Orawan - stock.adobe.com
November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein
Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Patients with PAH may experience issues with sleep | image credit: princeoflove - stock.adobe.com
November 14th 2024

Poor Sleep Quality Associated With Pulmonary Arterial Hypertension

Karen Jacobson-Sive
Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant predictor of sleep quality, independent of disease severity, according to this study.
patient and doctor - Halfpoint - stock.adobe.com.jpeg
November 6th 2024

Refinements to European Strategy Can Improve PAH-CHD Stratification

AJMC Contributor
When patients were re-classified based on the adjusted thresholds of N-terminal pro-brain natriuretic peptide and 6-minute walk distance and the inclusion of TAPSE rather than right atria area, classification of patients improved significantly.
Pulmonary hypertension | Image Credit: © Designpics - stock.adobe.com
November 1st 2024

PAH Treatment Outcomes Similar Regardless of Diagnosis Time

AJMC Contributor
The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
PAH concept | image credit: Ahmad - stock.adobe.com
October 23rd 2024

Early Use of Triple Oral Therapy May Lower Hospitalizations for PAH

AJMC Contributor
The comparative effectiveness study found that the addition of selexipag (Uptravi) to double oral therapy (DOT) reduced the risk of patients being hospitalized or having their disease progress.
Doctor holds lung model representing PAH | Image Credit: © Orawan - stock.adobe.com
October 16th 2024

Certain Immune Cells May Increase, Decrease PAH Risk

Gayle Turim Dickstein
Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension (PAH).
Mobility reduction may be an early sign of PAH | image credit: PrusarooYakk - stock.adobe.com
October 9th 2024

A Call for Consistent Digital Mobility Measurement Protocols in PAH

Gayle Turim Dickstein
As more researchers utilize digital technology to measure mobility in pulmonary arterial hypertension (PAH), a team calls for consistent protocols to make outcomes as meaningful as possible to patients and clinicians
Carboard cutout of lungs with a stethoscope and the words Pulmonary Hypertension | Image credit: Dzmitry - stock.adobe.com
October 4th 2024

Complementary Therapies Improve Quality of Life in PH

Gwen Mergian
Initial evidence suggests alternative approaches such as exercise, dietary modification, and psychosocial therapies may enhance traditional management of pulmonary hypertension.
Human lungs on scientific background | Image Credit: © Crystal light - stock.adobe.com
September 27th 2024

Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH

Gwen Mergian
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.
Man holding paper model of lungs | Image credit: Elena - stock.adobe.com
September 20th 2024

Comorbidities Require Special Treatment Consideration for PAH

AJMC Contributor
In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.
Months after the FDA's approval of sotatercept for treating PAH, the drug has gained European approval | image credit: wladimir1804 - stock.adobe.com
September 11th 2024

Sotatercept Gains European Approval for PAH for Use With Other Treatments

AJMC Contributor
The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial hypertension (PAH).
FDA | image credit: Araki Illustrations - stock.adobe.com
September 5th 2024

Inhaled PAH Therapy Gets Tentative Go-Ahead From FDA

Jared Kaltwasser
The tentative approval cannot take effect because a competing product was granted market exclusivity.
CPAP therapy can reduce the risk of hypertension during pregnancy | image credit: sokko_natalia - stock.adobe.com
August 24th 2024

CPAP Treatment Can Significantly Reduce Hypertensive Adverse Outcomes in Pregnancy

Gayle Turim Dickstein
When women with obstructive sleep apnea (OSA) carrying high-risk pregnancies collaborate with their health care providers to find the best individualized continuous positive airway pressure (CPAP) treatment, their risks of gestational hypertension and preeclampsia may drop appreciably
Clinician listening to child's heartbeat | image credit: Maria Sbytova - stock.adobe.com
August 19th 2024

Circulating HMGB1 Not a Reliable Biomarker in Pediatric PAH

Jared Kaltwasser
Though circulating high mobility group box-1 levels appear to be a biomarker for pulmonary arterial hypertension (PAH) in adults with congenital heart disease, the same is not true in pediatric patients.
Fruits and vegetable intake provides proven benefits for patients with hypertension | image credit: peangdao - stock.adobe.com
August 13th 2024

Fruit and Vegetables Outperform Medication and Baking Soda to Treat Hypertension 

Karen Jacobson-Sive
Patients with hypertension-related chronic kidney disease who increased daily fruit and vegetable consumption showed improved cardiovascular health and reduced blood pressure compared with participants who added baking soda to their diet or who received pharmacological-only treatment.
12345678
...
9>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo